Twirla is a contraceptive drug owned by Agile. Comprising of Ethinyl Estradiol and Levonorgestrel, it is delivered transdermally. The drug has been available in the market since February 14, 2020.
The generic versions of Twirla are expected to be available after August 26, 2028. The last of Twirla's patents expires on this date, paving the way for generic versions.
Twirla, containing Ethinyl Estradiol and Levonorgestrel, is used primarily as a contraceptive. The active ingredients work in combination to prevent ovulation, leading to its effectiveness.
Twirla holds three patents, all set to expire by August 2028, at which time Twirla generics may become available. Below are the details of the patents: